333. ハッチンソン・ギルフォード症候群 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 9 / 薬物数 : 7 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 5

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Lonafarnib
   Boston Children's Hospital
      2009   Phase 2   NCT00879034   United States
   Eiger BioPharmaceuticals
      2020   -   NCT03895528   -
   Monica E. Kleinman
      2007   Phase 2   NCT00425607   United States
   PRG Science & Technology Co., Ltd.
      2025   Phase 2   NCT06775041   United States
   The Children's Hospital Zhejiang University School of Medicine
      2021   -   ChiCTR2100050052   China
Lonafarnib, zoledronic acid, and pravastatin
   Boston Children's Hospital
      2009   Phase 2   NCT00916747   United States
Pravastatin
   Boston Children's Hospital
      2009   Phase 2   NCT00879034   United States
Progerinin
   PRG Science & Technology Co., Ltd.
      2025   Phase 2   NCT06775041   United States
      2020   Phase 1   NCT04512963   United States
Umbilical cord blood unit
   Bundang CHA Hospital
      2019   Phase 1/Phase 2   NCT03871972   Korea, Republic of
Zoledronic acid
   Boston Children's Hospital
      2009   Phase 2   NCT00879034   United States
Zoledronic acid, pravastatin
   Assistance Publique Hopitaux De Marseille
      2008   Phase 2   NCT00731016   France